Phase 2 study of carfilzomib + elotuzumab + dexamethasone for relapsed or progressed multiple myeloma after 1-3 prior treatment lines

Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2016
This article has no abstract
Epistemonikos ID: a3c06c67ba23557217d3ebd8f8a52067387c00b6
First added on: Apr 17, 2025